2024-11-01 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Analysis:

**Company Overview:** Teladoc Health Inc. is a telehealth company that provides virtual healthcare services, including medical consultations, mental health care, and chronic care management. 

**1. Performance vs. S&P 500:**

* **TDOC Cumulative Return:** 51.72%
* **VOO (S&P 500) Cumulative Return:** 129.91%
* **Return Gap:** -78.19% (relative gap: 1.15)

TDOC has significantly underperformed the S&P 500, lagging behind by approximately 78%.  

**2. Recent Price Movement:**

* **Last Price:** 8.98
* **5-Day Moving Average:** 8.91
* **20-Day Moving Average:** 9.1
* **60-Day Moving Average:** 8.22

TDOC has been trading slightly below its 20-day moving average but above its 60-day moving average, suggesting some short-term consolidation.

**3. Technical Indicators:**

* **RSI:** 47.45 (Neutral)
* **PPO:** -0.87 (Slightly Bearish)
* **Delta_Previous_Relative_Divergence:** 0.18 (+) (Short-term Upward Trend)
* **Expected Return:** 0.0% (Over the next two years, TDOC is expected to have a 0% outperformance compared to the S&P 500 based on long-term investment.)

While the technical indicators are mixed, the recent positive delta in the relative divergence suggests potential short-term upward momentum.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-10-31 | -0.19 | $0.64B |
| 2024-08-01 | -4.92 | $0.64B |
| 2024-04-26 | -0.49 | $0.65B |
| 2023-10-27 | -0.35 | $0.66B |
| 2023-10-31 | -0.35 | $0.66B |

The company has reported consecutive quarters of losses, and revenue growth has stalled.  The most recent earnings report did not meet analyst expectations.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin | 
|---|---|---|
| 2024-06-30 | $0.64B | 70.73% | 
| 2024-03-31 | $0.65B | 69.89% |
| 2023-12-31 | $0.66B | 70.72% |
| 2023-09-30 | $0.66B | 71.83% | 
| 2023-06-30 | $0.65B | 70.79% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $1.50B | -55.77% |
| 2024-03-31 | $2.29B | -3.58% |
| 2023-12-31 | $2.33B | -1.24% |
| 2023-09-30 | $2.29B | -2.49% | 
| 2023-06-30 | $2.30B | -2.84% |

TDOC has consistently generated positive revenue and profitability, but ROE has been negative, indicating the company has yet to become profitable.

**6. News & Recent Issues:**

* No recent earnings news was found in the last two days.

* **Recent Market Outlook:** While TDOC's recent price movements are positive, analysts have mixed opinions on its long-term viability.  Some believe the company has a promising future in the telehealth market, while others remain concerned about profitability and competition.  

* **Analyst Opinions and Performance Highlights:** FINBOLD reports TDOC has a moderate buy rating with a price target of $12.  Despite the challenging market environment, analysts believe TDOC has the potential to turn its performance around.

**7. Overall Analysis:**

TDOC is a growth stock in a rapidly expanding industry, but it faces significant challenges related to profitability and competitive pressures.  The company has recently shown some signs of improvement, but its long-term outlook remains uncertain. While the short-term technical indicators suggest potential upside, investors should remain cautious.  

**Conclusion:** TDOC has underperformed the S&P 500 and faces a challenging environment, but the company has potential due to its position in the growing telehealth sector. However, investors should proceed with caution due to the company's ongoing profitability issues and competition. 
